The economic consequences of a drug-drug interaction.
Shad
M U
MU
Marsh
C
C
Preskorn
S H
SH
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D001569:Benzodiazepines; D003863:Depression / Q000517:prevention & control; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D000077152:Olanzapine; D010300:Parkinson Disease / Q000188:drug therapy; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000494:pharmacology / Q000627:therapeutic use
D014150:Antipsychotic Agents; D005473:Fluoxetine; D001569:Benzodiazepines; D012642:Selegiline; D010890:Pirenzepine; D014282:Trihexyphenidyl; D006220:Haloperidol; D000077152:Olanzapine